Compare Inovio Pharmaceuticals Inc (INO) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.06 (market cap $101.95M), while Blue Owl Capital Inc. Class A Common Stock trades at $8.76 (market cap $6.01B). The key difference: Blue Owl Capital Inc. Class A Common Stock is far larger — about 59× Inovio Pharmaceuticals Inc's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 10.35% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| INO | OWL | |
|---|---|---|
Market Cap | $101.95M | $6.01B |
Volume | 2,985,847 | 24,327,195 |
Sector | Health | Financials |
52-Week High | $2.60 | $17.17 |
52-Week Low | $0.66 | $8.23 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $10.19B |
Dividend Yield | — | 10.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 but has beaten EPS estimates for three consecutive quarters. Key focus remains on the FDA's October 30, 2026 PDUFA decision for INO-3107, its lead candidate for recurrent respiratory papillomatosis. Analyst consensus is bullish with a $2.75 price target, though financials reveal significant losses with a -130,000% net income margin and negative cash flow from operations.
The investment case hinges on regulatory approval of INO-3107, offering substantial upside if successful. However, high cash burn, persistent losses, and dependence on financing pose severe risks. With 59% of analysts rating Buy, the stock presents a high-risk, high-reward opportunity suitable only for speculative investors comfortable with binary outcomes.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
